Lung abscess

Summary

Lung abscess (MONDO:0000744) is a disease with 8 GWAS associations across 6 studies and 6 clinical trials. Top therapeutic interventions include ampicillin and sulbactam. A subtype of abscess — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 8
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung abscess
Mondo ID	MONDO:0000744
EFO	EFO:1001362
MeSH	D008169
DOID	DOID:0060317
NCIT	C99090
SNOMED CT	73452002
UMLS	C0024110
MedGen	7397
Is cancer (heuristic)	no

Also known as: lung abscess · lung abscess (disease)

Data availability: 8 GWAS associations (6 studies) · 1 HPO phenotype.

Disease family

This is a subtype of abscess. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › abscess › lung abscess

Related subtypes (10): breast abscess, intracranial abscess, corneal abscess, pyoureter, splenic abscess, vitreous abscess, epidural abscess, peritonsillar abscess, liver abscess (disease), intersphincteric abscess

Genetics & variants

GWAS landscape

8 GWAS associations across 6 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs374750913	4e-13	MIR646HG - LINC01718	C	4.11
rs113763611	2e-12	GALNT17	A	4.34
rs188795859	6e-12	FGGY	C	3.17
rs148899520	1e-11	H2ACP1 - SERTM1	C	1.22
rs576101144	2e-11	RAP1BP2 - EZRP1	C	1.61
rs557643483	2e-11	AKR1C6P - U8	C	3.29
rs567562675	4e-11	CBLB	C	2.55
rs75650345	3e-07	BTC - HSPE1P23	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90652031	Liu TY	2025	3,091	198,125	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478124	Verma A	2024	1,330	446,327	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436215	Zhou W	2018	375	398,538	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90044061	Jiang L	2021	297	456,051	A generalized linear mixed model association tool for biobank-scale data.
GCST90480244	Verma A	2024	282	120,865	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90482075	Verma A	2024	282	120,865	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	8

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	7
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	4
intron_variant	4

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs374750913	20	61067291	C>A,T	0	intergenic_variant	MIR646HG - LINC01718	4e-13	Tier 4: intronic/intergenic
rs113763611	7	71150260	A>G	0.001	intron_variant	GALNT17	2e-12	Tier 4: intronic/intergenic
rs188795859	1	59364157	C>T	0.001	intron_variant	FGGY	6e-12	Tier 4: intronic/intergenic
rs148899520	13	36508674	C>T	0.006	intergenic_variant	H2ACP1 - SERTM1	1e-11	Tier 4: intronic/intergenic
rs576101144	3	104118339	C>T	0.002	intergenic_variant	RAP1BP2 - EZRP1	2e-11	Tier 4: intronic/intergenic
rs557643483	10	4914337	C>T	0	intron_variant	AKR1C6P - U8	2e-11	Tier 4: intronic/intergenic
rs567562675	3	105709567	C>A	0.001	intron_variant	CBLB	4e-11	Tier 4: intronic/intergenic
rs75650345	4	74811780	G>A		intergenic_variant	BTC - HSPE1P23	3e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Clindamycin Phosphate	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01045902	PHASE3	COMPLETED	BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia
NCT01085864	Not specified	ACTIVE_NOT_RECRUITING	Biomarkers for Diagnosis of Lung Nodules
NCT06657898	Not specified	RECRUITING	Complicated Pneumonia (CP) in Children in South-East Europe
NCT07247461	Not specified	NOT_YET_RECRUITING	Transthoracic Drainage of Lung Abscesses. A National Randomized Trial.
NCT07373171	Not specified	NOT_YET_RECRUITING	Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teaching Hospital
NCT01793688	Not specified	COMPLETED	Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AMPICILLIN	4	3
SULBACTAM	4	2